Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
1. Tevogen reports rNPV of $9B to $11B for TVGN-489 therapy. 2. TVGN-489 shows strong efficacy against SARS-CoV-2 in trials. 3. No toxicities were observed in clinical trials of TVGN-489. 4. Results indicate long-lasting immune response and viral elimination. 5. Tevogen plans ongoing updates regarding its product pipeline.